

---

**HOUSE COMMITTEE AMENDMENTS**

2026 Regular Session

Amendments proposed by House Committee on Insurance to Original House Bill No. 870  
by Representative Turner

---

1 AMENDMENT NO. 12 On page 1, delete lines 12 through 20 and on page 2, lines 1 through 9, and insert in the  
3 following definitions in lieu thereof:4 (1) "Biosimilar" means any biological product that is licensed under 42  
5 U.S.C. § 262(k) and has been listed in the U.S. Food and Drug Administration's  
6 (FDA) Database of Licensed Biological Products ("Purple Book") as biosimilar to  
7 or interchangeable with a reference biological product.8 (2) "Brand drug" means a drug for which an application has been approved  
9 under 21 U.S.C. § 355(c), or a biological product, other than a biosimilar, that is  
10 licensed under 42 U.S.C. § 262(a).11 (3) "Formulary" means a list of prescription drugs that is developed by a  
12 Pharmacy and Therapeutics (P&T) Committee or other clinical and pharmacy  
13 experts and represents a health plan's prescription drugs approved for use.14 (4) "Generic drug" means a drug for which an application has been  
15 approved under 21 U.S.C. § 355(j) and which has been listed in the FDA's Approved  
16 Drug Products with Therapeutic Equivalence Evaluations ("Orange Book") as  
17 therapeutically equivalent to a reference drug, even if the manufacturer of such drug  
18 applies a trade name to the drug.19 (5) "Reference listed drug" is the listed drug identified by the FDA as the  
20 drug product upon which an applicant relies in seeking approval of its application  
21 submitted under 21 U.S.C. § 355(j).22 (6) "Reference product" is a single biological product, licensed by the FDA  
23 under 42 U.S.C. § 262(a), against which a proposed biosimilar or interchangeable  
24 product is compared, and listed as a reference product in the FDA's Database of  
25 Licensed Biological Products ("Purple Book").26 (7) "Wholesale acquisition cost" carries the same definition as "wholesale  
27 acquisition cost" in 42 U.S.C. Section 1395w-3a(c)(6)(B).